DANNY C. REEVES, District Judge.
This matter is pending for consideration of Defendant Jack Conway's renewed motion to dismiss. [Record No. 36] Conway, the Kentucky Attorney General ("AG"), seeks dismissal of Plaintiff Merck Sharp & Dohme Corporation's ("Merck") complaint on abstention grounds. For the reasons explained below, the AG's motion will be denied.
The matter underlying this action arose from Merck's marketing and distribution of the prescription medication Vioxx.
Approximately one year into the Merck I proceeding, the AG retained outside counsel to assist with the Vioxx litigation. [Record No. 17-1, p. 2] Under the contract executed on September 30, 2010, private counsel agreed to be compensated by a contingency fee "to be withheld from any settlement award resulting from th[e] litigation." [Record No. 1-4, p. 3] The agreement also provides that the AG "retains the right at all times to direct the litigation in all respects." [Id., p. 5 (emphasis omitted)]
Merck filed suit against the AG in federal court on August 16, 2011, seeking a declaratory judgment and injunctive relief.
The AG argues in his renewed motion to dismiss that the Court should abstain
The abstention doctrine announced in Younger v. Harris, 401 U.S. 37, 91 S.Ct. 746, 27 L.Ed.2d 669 (1971), provides that when a state proceeding is pending, principles of federalism dictate that any federal constitutional claims should be raised and decided in state court without interference by the federal courts. See Pennzoil Co. v. Texaco, Inc., 481 U.S. 1, 17, 107 S.Ct. 1519, 95 L.Ed.2d 1 (1987); Tindall v. Wayne County Friend of the Court, 269 F.3d 533, 538 (6th Cir.2001). If a federal district court concludes that its resolution of the case before it would "directly interfere with ongoing state proceedings," then it must determine whether to abstain from hearing the case altogether. Mass. Delivery Ass'n v. Coakley, 671 F.3d 33, 45 (1st Cir.2012) (internal quotation marks omitted). The following requirements must be met for Younger abstention to apply: (1) there must be an ongoing state judicial proceeding; (2) the proceeding must implicate important state interests; and (3) there must be an adequate opportunity in the state proceeding to raise constitutional challenges. Middlesex Cnty. Ethics Comm. v. Garden State Bar Ass'n, 457 U.S. 423, 432, 102 S.Ct. 2515, 73 L.Ed.2d 116 (1982); see Kelm v. Hyatt, 44 F.3d 415, 419 (6th Cir.1995).
The threshold issue in any Younger analysis is the "question of whether `interference' exists." Coakley, 671 F.3d at 40. "`In the typical Younger case, the federal plaintiff is a defendant in ongoing or threatened state court proceedings seeking to enjoin continuation of those state proceedings.'" Devlin v. Kalm, 594 F.3d 893, 894 (6th Cir.2010) (quoting Crawley v. Hamilton Cnty. Comm'rs, 744 F.2d 28, 30 (6th Cir.1984)). Thus, if the "plaintiffs are not attempting to use the federal courts to shield them from state court enforcement efforts," there is no basis for Younger abstention. Id. at 895 (internal quotations omitted).
Merck asserts that it is "not asking the Court to enjoin the AG from suing it." [Record No. 40, p. 5 (emphasis omitted)] Instead, it maintains that it seeks an "injunction barring the AG from pursuing his lawsuit against Merck with contingency-fee counsel." [Id. (internal quotation marks omitted)] The AG argues that such an injunction would unduly interfere with the state proceeding because it would be "tantamount to forcing the Attorney General not to use outside counsel at all," due to the limited resources of the AG's office. [Record No. 45, p. 3]
The Court need not decide whether enjoining the use of contingency-fee counsel would interfere with the state court action to the extent that Younger abstention would be appropriate because Merck has expressly requested the type of relief contemplated in Younger itself. See 401 U.S. at 39, 91 S.Ct. 746 (explaining that the federal plaintiff filed a complaint "asking [the district] court to enjoin the ... District
If the Court were to grant the injunction sought by Merck, it would halt the state court action. This would, by definition, "unduly interfere" with the state proceeding.
Although the Younger Court dealt specifically with the issue of federal court interference with ongoing state criminal proceedings, the doctrine has been expanded to apply to most civil litigation in which the state itself is a party. See Huffman v. Pursue, Ltd., 420 U.S. 592, 607, 95 S.Ct. 1200, 43 L.Ed.2d 482 (1975) (holding that Younger abstention applies in federal action challenging state civil nuisance proceeding). Here, the Commonwealth of Kentucky is a party to the action. Moreover, because the state proceeding at issue in this case is a civil prosecution under the KCPA, it involves an important state interest. Marathon Petroleum Co. v. Stumbo, 528 F.Supp.2d 639, 645 (E.D.Ky.2007) ("Courts have recognized in the Younger analysis that states have a strong interest in protecting consumers and in administering their consumer protection statutes."). Thus, the Court concludes that this prong of Younger has been met.
The next "inquiry is whether the state proceedings afford [Merck] an adequate opportunity to raise [its] constitutional claims." Moore v. Sims, 442 U.S. 415, 430, 99 S.Ct. 2371, 60 L.Ed.2d 994 (1979). The "burden on this point rests on the federal plaintiff to show `that state procedural law bar[s] presentation of [its] claims.'" Pennzoil Co. v. Texaco, Inc., 481 U.S. 1, 14, 107 S.Ct. 1519, 95 L.Ed.2d 1 (1987) (quoting Moore, 442 U.S. at 432, 99 S.Ct. 2371). The AG maintains that "the
Merck argues that the claims raised in this action could not be asserted in Merck I because they are collateral to that proceeding. Collateral issues are those that "could neither be proven as part of the state case-in-chief nor raised as an affirmative defense." Id. If a constitutional claim would be "collateral" to the state proceeding, then there is no opportunity to raise that issue in the state forum. Id. Thus, if Merck's constitutional claims are collateral to the issues being litigated in Merck I, the Court should not abstain under Younger.
Merck contends that its constitutional claims could not be heard by the Franklin Circuit Court without first filing a new complaint and then moving to consolidate that action with Merck I. The AG counters that Merck's "claims can easily be raised in the state case-in-chief as a Motion to Disqualify Counsel." [Record No. 45, p. 17] Although it is debatable whether Merck's claims fall within the "collateral issue" exception created by Habich,
The last remaining prong of the Middlesex test is whether the state court action in Merck I constitutes an "ongoing state judicial proceeding." 457 U.S. at 432, 102 S.Ct. 2515. Merck contends that the Court must abstain under Younger only if it concludes that the underlying state court proceeding was already pending when Merck filed suit in federal court. It thus asserts that, because the removal to federal court occurred before Merck sought injunctive relief from this Court, the AG has failed to make out the "ongoing state proceeding" prong required for Younger abstention. The AG, on the other hand,
The true nature of the "ongoing state proceeding" requirement lies somewhere between the parties' two positions: this prong is met if (1) the state proceeding was initiated before the federal litigation, or (2) "state [] proceedings are begun against the federal plaintiffs after the federal complaint is filed but before any proceedings of substance on the merits have taken place in the federal court." Hicks v. Miranda, 422 U.S. 332, 349, 95 S.Ct. 2281, 45 L.Ed.2d 223 (1975). Thus, the Court must consider the timing of the two pending actions to determine whether this prong of the Middlesex test has been established.
The AG concedes that Merck I was not "literally pending in state court at the time this action was filed in this Court."
As a general rule, the "proper time of reference for determining the applicability of Younger abstention is the time that the federal complaint is filed." Zalman v. Armstrong, 802 F.2d 199, 204 (6th Cir.1986). However, there is an exception to this rule. In Hicks, the Supreme Court held that a district court may abstain even if the federal suit was filed before the state court proceeding, as long as the state proceeding is commenced "before any proceedings of substance on the merits" take place in the federal action. 422 U.S. at 349, 95 S.Ct. 2281 (finding abstention appropriate where federal plaintiffs were charged in state court "on the day following completion of service of the [federal] complaint"). In other words, if the state court proceeding is not pending at the time the federal complaint is filed, Younger abstention may still be appropriate, but only if the federal action is "in an embryonic stage and no contested matter ha[s] been decided." Doran v. Salem Inn, Inc., 422 U.S. 922, 929, 95 S.Ct. 2561, 45 L.Ed.2d 648 (1975) (finding state court proceeding ongoing where criminal summonses were issued in state court "on the
Unfortunately, "the contours of what defines a proceeding of substance have yet to be established by the Supreme Court or the Sixth Circuit." Kalniz v. Ohio State Dental Bd., 699 F.Supp.2d 966, 971 (S.D.Ohio 2010). The AG asserts that no "proceedings of substance" took place in Merck II before the Merck I litigation was pending in state court. He supports this contention by pointing out that this Court issued opinions on the motion for preliminary injunction and the motion to dismiss on March 21, 2012 and March 23, 2012, respectively — days after Merck I was remanded to state court.
Based on the extensive development of this federal action before the remand of Merck I on March 20, 2012, it certainly appears that the AG has engaged in active litigation in this federal forum. Cf. Cradle of Liberty Council, Inc. v. City of Philadelphia, No. 08-2429, 2009 WL 3921140, at *4 (E.D.Pa. Nov. 18, 2009) ("While not dispositive, the filing of a Motion to Dismiss on the substance of [the plaintiff's] federal claims demonstrates the [defendant's] pursuit of this case in a federal forum."). On the other hand, it is true that the Court did not enter an opinion on the merits of the case until one day after Merck I was remanded to state court.
Neither Hicks nor Doran requires such strict adherence to the federal action's timeline that the Court must abstain based only on a one-day (or even three-day) lapse of time between the filing of a state action and a federal court's ruling on a substantial
Here, several factors weigh in favor of a conclusion that proceedings of substance had taken place in this Court before Merck I was pending in state court: (1) the federal action had been pending for over seven months when the state court proceeding was remanded on March 20, 2012; (2) on the date of the remand, there were two important motions that were fully briefed and ripe for adjudication; and (3) the Court held a scheduling conference on October 6, 2011, during which the parties advised the Court about their positions on those two motions. Based on these facts, the Court concludes that the federal action, Merck II, was well beyond an "embryonic stage" by the time the state action was pending. Doran, 422 U.S. at 929, 95 S.Ct. 2561. The fact that the Court's actual opinions on the motion for preliminary injunction and motion to dismiss were entered a few days after the state court proceeding was remanded — meaning, of course, that the Court had spent considerable time on those opinions prior to the date Merck I was remanded to Franklin Circuit Court — does not defeat this conclusion. Because the state proceeding in Merck I was not "ongoing," abstention is not appropriate under the principles of Younger.
Abstention is not required under Younger v. Harris, 401 U.S. 37, 91 S.Ct. 746, 27 L.Ed.2d 669 (1971). Accordingly, it is hereby